Second-generation antipsychotics (SGA) are associated with weight gain and metabolic alterations including hyperglycemia, dyslipidemia, hypertension and metabolic syndrome. These metabolic side effects increase cardiovascular risk and are related to medication non-compliance. Patients without previous exposure to these or other antipsychotic drugs (naive patients) seem to be more prone to develop these metabolic abnormalities. The mechanisms behind weight gain can be an increase in food intake and/or a decrease in energy expenditure. This review comprehensively examines the current knowledge on the impact of these drugs on food intake and energy expenditure. The influence of these drugs on appetite and food intake (total caloric intake and food sources) is reviewed as well as the evidence of abnormal eating behaviors. The studies evaluating the effect on resting energy expenditure are critically examined, taking into account the influence of body composition and previous exposure to antipsychotics (naive vs non-naive patients). Finally, the influence of these drugs on physical activity is also discussed. The knowledge of the mechanisms of weight gain in patients starting these drugs may be useful to further prompt research in this field and ameliorate the metabolic side effects associated with these treatments.
INTRODUCTION
Second-generation antipsychotics (SGA) are widely used in the treatment of psychiatric disorders, mostly in psychosis, in children and adults. 1, 2 The overall prevalence of antipsychotic prescription has at least doubled in the past decade in the United States and Europe, 3, 4 mainly due to the increased use of SGA and to longer duration of treatment. 5 However, despite the widespread use of these drugs, their efficacy (except for clozapine) seem to be similar to firstgeneration antipsychotics (FGA) in children and adults, and the major benefit over them is the less extrapyramidal side effects (akathisia, tardive diskinesia and parkinsonism). [6] [7] [8] [9] [10] Since the introduction of SGA in the treatment of psychotic disorders, there has been an increase in metabolic side effects, such as weight gain, dyslipidemia, diabetes and metabolic syndrome, in comparison with previous studies with FGA or without treatment. 11, 12 In children and adults, these metabolic abnormalities are most commonly observed with clozapine and olanzapine, to a moderate extent with quetiapine and risperidone and rarely with aripiprazole and ziprasidone. 6, 13 These differences may be due to their pharmacological profiles, as besides being partial or transient D 2 receptor antagonists, many of them are antagonists of central nervous system receptors involved in the control of body weight (5-HT 2c , muscarinic, histaminic H 1 and a 1 -adrenergic receptors). 14 The weight gain induced by these drugs is usually centrally distributed, with an increase in waist circumference. 15, 16 This is associated with insulin resistance and metabolic syndrome, which increase the risk of diabetes and cardiovascular disease. 17 Furthermore, metabolic abnormalities increase the risk of poor adherence to medication.
Recent data suggest that the effect of SGA drugs on weight gain may have been underestimated in chronically treated adult populations, as the weight gain is greater in children compared with adult series and in naive patients compared with non-naive patients. 18 Moreover, there is consistent interindividual variation, 17 probably resulting from poorly understood drug-gene-environment interactions. 18 Maintenance of weight is the result of a balance between energy intake and expenditure. The mechanisms underlying the increase in body mass in people taking SGA remain unknown, and may include changes in food intake and energy expenditure. In this article, we will review the current knowledge on the contribution of food intake and energy expenditure to weight gain in these patients.
METHODS
With the objective of studying the mechanisms of weight gain in patients taking SGA, we performed a search in Medline (PubMed) and Central (Cochrane Library) Databases of studies published between 1990 and July 2013 with the keywords 'second-generation antipsychotics' OR 'atypical antipsychotics' AND 'mechanisms of weight gain' OR 'food intake' OR 'appetite' OR 'energy expenditure' OR 'resting energy expenditure' OR 'physical activity' (PA). We restricted the search to studies in humans, published in English.
We reviewed the abstracts manually and completed the search with relevant articles from the selected papers' reference list. A total of 22 studies fulfilled these criteria (Figure 1 ).
RESULTS
The studies retrieved are reviewed here and with a specific focus to the effects of SGA on appetite and food intake, resting energy expenditure (REE) and PA.
Effects of SGA on appetite and food intake We identified 10 studies that evaluated the effect of these drugs on appetite and food intake (Table 1) . Three studies included healthy adults [19] [20] [21] and seven included patients. 15, [22] [23] [24] [25] [26] [27] The study design was longitudinal in six studies and cross-sectional in four. Four studies were randomized [19] [20] [21] 26 and three of them were placebo-controlled. [19] [20] [21] Five studies evaluated food intake, 15, [19] [20] [21] 23 five appetite and eating behaviors 19, 21, 22, 24, 25 and two the presence of eating disorders in these subjects. 26, 27 Food intake was recorded using 24-h dietary recalls or 24-h food records for several days. Two studies performed a feeding laboratory assessment including one or more standardized meals to evaluate appetite by means of visual analog scales (VAS) and eating behaviors with the Three Factors Eating Behavior Questionnaire (TFEBQ) to measure cognitive dietary restraint, disinhibition and susceptibility to hunger. 19, 22 Other studies used other validated and non-validated questionnaires to evaluate appetite and eating behaviors, 21, 24, 25 as well as the presence of eating disorders. 26, 27 In healthy volunteers hospitalized for 12 nights and treated with olanzapine, aripirazole or placebo on days 6-12, total calorie intake on the test days (days 2 and 11) was similar among treatments and no significant differences in hunger ratings were found among the interventions. 21 In longer treatments (2-4 weeks) in healthy volunteers and adolescents, 24-h food intake increased significantly 18% and 27.7%, respectively, without change in diet composition. 20, 15 Figure 1. Flow chart of included and excluded studies in the search. However, in another study there was a difference in the macronutrient composition of the diet between patients treated with different antipsychotics (clozapine vs risperidone). 23 The clozapine group consumed more fat (36±6.7% vs 30.9 ± 5.7%, P ¼ 0.007) and saturated fat (13.7 ± 3.4% vs 10.6 ± 3%, P ¼ 0.007), less carbohydrates (48.8 ± 7.5% vs 55.7±9.5%, P ¼ 0.009) and more proteins (16.2±3.9% vs 13.8±3.4%, P ¼ 0.036). After a standardized breakfast, patient's degree of hunger was higher compared with controls (P ¼ 0.03) and satiety quotients were lower using a VAS (Po0.02). 22 Patients had significantly higher cognitive dietary restraint, disinhibition and susceptibility to hunger scores than the control group in the TFEBQ (Po0.05). 22 In another study conducted in 153 patients with schizophrenia, those treated with SGA were more reactive to external eating cues (P ¼ 0.035) and the TFEQ disinhibition and hunger scores increased according to the body mass index (P ¼ 0.003; P ¼ 0.017). 24 In a large secondary analysis of four clinical trials that evaluated the influence of appetite changes using different scales on weight gain in 805 patients treated with olanzapine for 12-24 weeks, only in two of the studies the increase in appetite correlated with weight gain. The major correlation was between early weight changes (2-4 weeks) and overall weight changes. 25 Also, clozapine and olanzapine induced food craving and binge eating in up to 48.9% and 16.7% of patients, respectively, as well as full-blown eating disorders in a small percentage of them (4.3-11.1%). 26, 27 Effects of SGA on REE We identified 14 studies that evaluated REE in subjects on SGA treatment (Table 2) . Four studies included healthy volunteers 19, 20, 28, 29 and 10 studies included patients. 15, 16, [30] [31] [32] [33] [34] [35] [36] [37] The study design was longitudinal in nine studies and cross-sectional in five. Two of the studies were case studies including one and three patients, respectively. 34, 35 Only three studies were randomized 19, 20, 29 and two were placebo-controlled. 19, 20 REE was measured by indirect calorimetry (IC) using a metabolic cart or a portable device. Body composition was evaluated by different methods: bioimpedance analysis, dual-energy X-ray absorptiometry (DEXA) and isotopes.
In healthy volunteers, REE per kg fat-free mass (FFM) did not change significantly during a 2-week treatment with SGA 19, 20 and even in shorter treatments (8 days) with olanzapine, REE and weight maintained stable 28 and did not differ among the groups (orally disintegrating tablets (ODT), oral standard tablets (OST) or no intervention). 29 In patients with schizophrenia (taking and 30 In three studies including psychotic patients taking clozapine or olanzapine for more than 6 months, measured REE with IC was 16-30% lower than predicted by different equations (Harris-Benedict, Schoefield, Mifflin-St Jeor and others). [31] [32] [33] A decrease in REE has also been reported in case studies, in an adult patient after 1 month of olanzapine 34 and in three adults after 1 month of clozapine. 35 However, recent longitudinal studies have found controversial results in REE corrected by body mass or FFM. 15, 16, 36, 37 In a study with 10 male adolescents taking a 4-week course of olanzapine, no effect on REE corrected by body mass (REE per kg) was detected, although only one patient was treatment naive. 15 Another study of nine adults in their first psychotic episode revealed no change in REE measured by IC after 12 weeks of treatment with olanzapine. 36 In this study, the first evaluation was performed within 7 weeks of starting therapy with antipsychotic drugs, REE was not measured in the standard conditions (after an overnight fast) and body composition was estimated by dualenergy X-ray absorptiometry. Another study compared REE measured by IC in 31 patients with schizophrenia on SGA treatment for more than 4 months with 31 weight-matched controls. 37 They found a significantly lower REE in cases compared with controls, which equaled when adjusted by FFM (measured by deuterium dilution) in the analysis of covariance.
In a prospective study of 54 adolescents, naive or quasinaive patients (o72 h exposure to antipsychotics) starting treatment with SGA in monotherapy (olanzapine, quetiapine or risperidone) 16 REE did not change significantly during the 12-month follow-up, despite the weight gain during treatment. REE adjusted for body weight (REE per kg) decreased significantly (P ¼ 0.027) and the REE per percentage FFM ratio increased (P ¼ 0.007) and was correlated with the weight increase at 12 months (r ¼ 0.69, P ¼ 0.004).
Some authors have studied the changes in the respiratory quotient (RQ) in the IC in these subjects finding controversial results. 16, [28] [29] [30] 36, 37 In two studies with healthy volunteers with a very short treatment with olanzapine, the RQ remained stable 28 and did not differ among the groups (ODT, OST or no intervention). 29 In one study, there was a low fat oxidation according to the RQ after 4 months of SGA treatment in patients compared with controls. 37 Similar results were found in another study in which RQ increased 14%, and there was a positive correlation between the change in RQ and weight (r ¼ 0.73, Po0.03). 36 However, these changes in RQ were not observed in other studies. 16, 30 Effects of SGA on PA We identified six studies that evaluated PA in subjects taking SGA (Table 3) . Three studies were performed in healthy volunteers 20, 21, 29 and the three others in patients. 15, 16, 38 The design of the study was longitudinal in five and cross-sectional in one. Three studies were randomized 20, 21, 29 and two of them were placebocontrolled. 20, 21 The methods used to measure or estimate PA were accelerometers, pedometers, heart rate monitors, doubly labeled water (DLW) and a 3-day PA questionnaire.
In the three studies with healthy volunteers who followed a 7 days to 2 weeks course of treatment, the activity level measured by the accelerometer or pedometer did not change significantly during the study. 20, 21, 29 In one study with 10 male adolescents on a 4-week olanzapine treatment (only one of them was naive), daily PA was very low before and after treatment, determined through accelerometer and heart rate monitoring. 15 Total energy expenditure (TEE) and activity energy expenditure were measured using DLW in eight men with schizophrenia who had been taking clozapine for more than 6 months. 38 TEE was significantly different to World Health Organization recommendations (more than 20% lower). In this study, the PA level was calculated as the ratio of TEE:REE. The patients had a low PA level (1.39 ± 0.27), in the range of sedentary people (o1.5).
Energy expenditure, recorded by a 3-day PA questionnaire, increased in a prospective study with adolescents taking SGA for 12 months. However, this result may be biased because the first measurement was performed during the hospitalization, when PA is usually very low. 16 
DISCUSSION
Psychotic patients have increased metabolic and cardiovascular disease risk, 17, 39 which may result from the interaction of different factors, such as patient genetic background, underlying disease, unhealthy lifestyle and medication. 18 Since the introduction of SGA there has been an increase in weight gain and metabolic side effects in these patients. 11, 12 Effects of SGA on food intake, REE and physical activity C Cuerda et al
The main prognostic factors for weight gain under this treatment have been young age, naive patients, low body mass index before treatment, antipsychotic type and dose and polypharmacotherapy. 18 Recent data in antipsychotic-naive patients suggest that the magnitude of weight gain has been consistently underestimated by studies in chronically treated adult populations. 40, 41 This may be one of the reasons responsible for the greater weight gain and metabolic effects observed in children and adolescents compared with adult studies. 18 The maintenance of body mass is a balance between food intake and energy expenditure. These mechanisms are tightly controlled by a network of neurotransmitters and neuropeptides. SGAs are antagonists of different central nervous system receptors involved in the control of body weight (serotoninergic, histaminergic, dopaminergic and/or adrenergic). Among them, the most reliable predictor of weight gain seems to be the H 1 receptor. 42 The studies using healthy volunteers have the advantage of avoiding contributing effects of illness and illness-related lifestyle factors, avoiding also previous treatments with psychotropic medications that can wash out the drug effect being examined. Likewise, subacute treatment is more likely to avoid changes in body composition, which allows a cleaner glimpse at the direct effects of the antipsychotic medication on energy expenditure. On the other hand, the doses used in studies with healthy volunteers are lower than that in the clinical practice and may influence the effects of these drugs.
Effects of SGA on appetite food intake Psychotic patients are characterized by sedentary lifestyles and poor dietary intake. 43, 44 These patients are less likely to make healthy dietary choices compared with the general population, including more fat and sugar and less fiber in their diet. [44] [45] [46] Most of the studies on food intake in volunteers and patients treated with SGAs show an increase in food intake during treatment. 15, 20 This increase was especially relevant in patients and points out that this mechanism may contribute to weight gain in these patients. The changes in the macronutrient composition of the diet with increase in total and saturated fat can contribute to overweight, obesity and metabolic abnormalities. 23 The studies support an increase in appetite in volunteers (with 2-week SGA exposure) and patients and changes in eating habits. 19, 22, 24, 25 Even some patients develop craving, binge eating and eating disorders. 26, 27 However, some authors support that early weight changes may be a more useful predictor for long-term weight changes than early score changes on appetite assessment scales. 25 The role of leptin and ghrelin changes during these treatments may be important in the weight gain as they act in opposite direction in balancing energy homeostasis and body weight regulation. While leptin is an adipocyte-derived hormone that positively correlates with fat mass and exerts an anorexigenic action, ghrelin is a gut hormone that stimulates fat mass accumulation and promotes food intake with a net orexigenic effect. 47 Studies in humans have consistently shown that SGA increase levels of circulating leptin. 48, 49 However, leptin increases that should decrease food intake occurred concurrent with weight gain, indicating that leptin increases are a consequence of rather than a cause of antipsychotic-induced weight gain, although the development of relative or absolute leptin resistance has also been reported. 49 Reports regarding the appetite-stimulating hormone, ghrelin, have been mixed, probably due to the heterogeneity of patients included and treatment types. A careful review of the literature suggests that fasting morning ghrelin levels decrease early in the course of antipsychotic treatment and then increase after chronic exposure. Effects of SGA on energy expenditure TEE is the energy required by the body daily and it is determined by the sum of three components: basal energy expenditure, PA and the diet-induced thermogenesis. 50 Basal energy expenditure is the minimum rate of energy expenditure in an awake, relaxed person lying on a bed after an overnight fast under controlled conditions of temperature and humidity. It is the largest component of energy expenditure, comprising 68-80% of TEE, and is determined by several factors, including body composition (mostly FFM), age, gender and ethnicity. REE is often used interchangeably with basal energy expenditure, although it is not measured under such strict conditions of temperature and humidity, and includes the stress of the underlying disease. PA is the other important component of energy expenditure, and can vary widely between patients. Finally, diet-induced thermogenesis is the energy required for the digestion, absorption, usage and storage of nutrients after food intake and comprises o10% of TEE.
REE can be measured by IC or estimated by equations. Early studies using more basic methods suggested that patients with schizophrenia had lower energy expenditure when resting, and, more recently, it was confirmed in patients taking and not taking medication. 30 The effect of SGA on REE in the studies reviewed show controversial results. 15, 16, 19, 20, 28, 29, 36, 37 These studies differ in their design (cross-sectional vs longitudinal), subjects (healthy volunteers vs patients), previous exposure to antipsychotics (naive vs non-naive) and methods to evaluate energy expenditure and body composition (IC, bioimpedance analysis, dual-energy X-ray absorptiometry, isotopes), which may explain the different results among them.
The fact that measured REE was lower than predicted with different equations can be interpreted as a hypometabolic state because of the effect of the medication, or an overestimation of the formulas in these patients. [31] [32] [33] The conflicting results on the effect of SGA in REE in longitudinal studies may reflect the differences in the study populations. In those studies that included non-naive patients, the carrying over effect from previous drugs could have decreased baseline REE in the treatment-experienced patients. 15 However, in the only study that included only naive patients, the authors reported a decrease in REE per kg during the follow-up that was correlated with the weight gain. 16 Even if not ideal, FFM seems to be the best available predictor of basal metabolic rate and, in most cases, tends to eliminate the differences observed between sexes and between overweight and normal-weight people and the decline of basal metabolic rate with age. 51 However, some authors consider that it is incorrect to express metabolic rate data per kilogram FFM to standardize values of control and experimental subjects, as it assumes that the Figure 2 . Mechanisms of weight gain in patients taking SGA: higher food intake, lower energy expenditure (controversial results in the literature on the effect of SGA on REE, low physical activity in these patients).
Effects of SGA on food intake, REE and physical activity C Cuerda et al regression between the dependent variable and the covariate is linear and has a zero intercept and this rarely happens with biological relationships. 52 They consider more appropriate to compare by multiple-regression analysis, the slopes and intercepts of the regression lines between metabolic rate and FFM in the different groups.
In conclusion, with the current studies we still do not know if the changes in REE can be explained by the changes in weight and body composition or is a direct effect of these drugs that could be partly responsible for the weight gain under these treatments.
Some authors have speculated with a decreased fat oxidation (shown as a high RQ, during IC) as the cause responsible for weight gain in these patients. 36, 37 As RQ increases with overfeeding, reflecting anabolism and lipogenesis, it should be considered with caution as the cause of weight gain in these patients. On the other hand, some authors think that the real value of RQ is to assess the reliability of the IC results (if the RQ is within normal range 0.67-1.3) but it is useless to study the substrates oxidation in the body. 53 Previously, accurate measures of TEE were not possible outside of specialist research settings. Recent advances in measurement techniques have made it possible to reliably assess TEE in freeliving conditions; DLW is considered the gold standard methodology to assess TEE and hence activity energy expenditure in them. Other methods used for measuring PA are accelerometers, sensors of heat and movement and the PA records. 50 PA is low in these patients although it is not clear if this effect is due to the medication or the disease. 15, 38 PA may be an additional variable to take into account as it is reduced in many patients on SGA treatment.
CONCLUSIONS
The studies evaluating the mechanisms of weight gain in patients on SGA treatment are scarce and heterogeneous, with great difference in the design that make difficult to compare the results. The studies using healthy volunteers have the advantage of avoiding contributing effects of illness and illness-related lifestyle factors, avoiding also previous treatments with psychotropic medications that can wash out the drug effect being examined, although the doses used and the time of exposure to the drug in these studies do not reflect the common clinical practice. There are few studies conducted in antipsychotic-naive patients and additional research in this area is urgently needed, as these are the most susceptible patients to the metabolic side effects of these drugs. SGAs are associated with an increase in appetite and food intake that can contribute to weight gain. The data on REE are still controversial, and although it seems to decrease in most of the studies, this may reflect the change in body composition. PA is low in these patients, especially in comparison with normal people.
It should be included the cause-effect difficulties in the interpretation of the results and the necessity to conduct longitudinal studies with drug-naive patients with large samples in which potential confounding variables are controlled for (e.g. weight, FFM). To decrease the impact of these drugs on weight gain, it may be important to implement measures leading to increase FFM (especially physical exercise) that could help to increase REE in these patients. Lifestyle recommendations involving reduced calorie intake and appropriate selection of food with an increase in PA should be prescribed in all the patients starting these treatments.
